Anlon Healthcare Reports 259% Profit Increase in Q2 FY26

Anlon Healthcare Limited has released its unaudited financial results for the second quarter (Q2) and half-year (H1) of the fiscal year 2026. The company reported a substantial increase in its financial performance metrics for the period ending September 30, 2025. The financial results were submitted in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

For Q2 FY26, Anlon Healthcare reported a Total Income of ₹52 crore, representing a 116% increase from ₹24 crore in Q2 FY25. The company’s EBITDA for the same period was ₹14 crore, up 82% from ₹8 crore in the previous year. The Profit After Tax (PAT) saw a significant rise of 259%, reaching ₹9 crore compared to ₹3 crore in Q2 FY25. The PAT Margins improved by 713 basis points, reaching 18%.

In the half-year results for FY26, Anlon Healthcare’s Total Income was ₹86 crore, marking a 38% increase from ₹62 crore in H1 FY25. The EBITDA for H1 FY26 was ₹20 crore, a 38% increase from ₹15 crore in the previous year. The PAT for H1 FY26 doubled to ₹13 crore from ₹6 crore in H1 FY25, with PAT Margins improving by 481 basis points to 15%.

Anlon Healthcare’s operational highlights include a diversified product portfolio with 65 commercialized products, 28 in pilot-stage, and 49 in lab-stage. The company maintains a robust regulatory platform with 21 global DMF filings and a WHO-GMP certified manufacturing facility. The manufacturing strength is underscored by a 400 MTPA installed capacity at its Rajkot facility, operating at approximately 84% utilization with zero-liquid-discharge operations. The company also operates four in-house R&D labs focused on new product development and quality excellence.

The company’s strategic focus includes expanding its active pharmaceutical ingredients (API) portfolio and enhancing its global presence. Anlon Healthcare is among the few Indian manufacturers of APIs such as Loxoprofen Sodium Dihydrate, Ketoprofen, and Dexketoprofen Trometamol, which are used for pain and inflammation management. The company serves multiple sectors, including pharmaceuticals, nutraceuticals, personal care, and animal health.

Anlon Healthcare Limited was incorporated in 2013 and is headquartered in Rajkot, Gujarat. The company is a research-driven manufacturer of high-purity advanced pharmaceutical intermediates and APIs. It continues to advance health through innovation, quality, and sustainability, with a global presence across more than 15 countries.